Target Name: MCM3
NCBI ID: G4172
Review Report on MCM3 Target / Biomarker Content of Review Report on MCM3 Target / Biomarker
MCM3
Other Name(s): Cervical cancer proto-oncogene 5 | MGC1157 | OTTHUMP00000016600 | RLF subunit beta | DNA replication licensing factor MCM3 | HCC5 | p102 | minichromosome maintenance deficient 3 | RLFB | MCM3 variant 1 | hRlf beta subunit | minichromosome maintenance complex component 3 | Minichromosome maintenance complex component 3 | MCM3_HUMAN | P102 protein | MCM3 minichromosome maintenance deficient 3 | P1-MCM3 | Minichromosome maintenance complex component 3, transcript variant 1 | DNA replication factor MCM3 | DNA replication licensing factor MCM3 isoform 1 | P1.h | Minichromosome maintenance deficient 3 | Replication licensing factor, beta subunit | cervical cancer proto-oncogene 5 | replication licensing factor, beta subunit | DNA polymerase alpha holoenzyme-associated protein P1

Targeting MCM3: A Potential Drug Treatment for Cervical Cancer

Cervical cancer is a leading cause of cancer-related deaths worldwide, with over 12,000 new cases and over 6,000 deaths in the United States alone in 2020. Despite advances in cancer treatment, there remains a need for new and more effective therapies to treat this aggressive and often lethal form of cancer.

One potential drug target for cervical cancer is the protein MCM3, also known as proto-oncogene 5. MCM3 is a transcription factor that plays a critical role in the development and progression of cervical cancer. It is expressed in high levels in the cells of cervical cancer and has been shown to promote the growth and survival of cancer cells.

In order to better understand the role of MCM3 in cervical cancer, researchers have conducted a series of studies to investigate its potential as a drug target. These studies have shown that targeting MCM3 with drugs can result in significant improvements in the treatment of cervical cancer.

One of the most promising approaches to targeting MCM3 is the use of inhibitors, such as those that target the DNA-binding activity of MCM3. These inhibitors can be delivered directly to the cells to prevent MCM3 from binding to DNA and thereby inhibit its ability to promote cancer cell growth.

Another approach to targeting MCM3 is the use of monoclonal antibodies, also known as MAbs. MAbs are laboratory-produced antibodies that can be directed against specific proteins and are often used to block the activity of MCM3 in cancer cells. By using MAbs to target MCM3 , researchers have been able to significantly reduce the growth of cancer cells and improve the treatment outcomes in cervical cancer patients.

In addition to inhibitors and MAbs, researchers have also explored the use of small molecules and other chemical compounds to target MCM3 in cervical cancer. These compounds have been shown to be effective in inhibiting the activity of MCM3 and have the potential to be used as either standalone treatments or in combination with other therapies.

While the use of MCM3 as a drug target is still in its early stages, it holds great promise as a new treatment option for cervical cancer. Further research is needed to fully understand the role of MCM3 in this disease and to develop more effective therapies that can be used to treat cervical cancer.

In conclusion, MCM3 is a potential drug target for cervical cancer that has the potential to significantly improve treatment outcomes for this aggressive form of cancer. While more research is needed to fully understand its role, the use of inhibitors, monoclonal antibodies, and small molecules has shown promise in its potential as a new treatment option for cervical cancer. With further research, it is possible that MCM3 will become a valuable tool in the fight against this devastating disease.

Protein Name: Minichromosome Maintenance Complex Component 3

Functions: Acts as component of the MCM2-7 complex (MCM complex) which is the replicative helicase essential for 'once per cell cycle' DNA replication initiation and elongation in eukaryotic cells. Core component of CDC45-MCM-GINS (CMG) helicase, the molecular machine that unwinds template DNA during replication, and around which the replisome is built (PubMed:32453425, PubMed:34694004, PubMed:34700328, PubMed:35585232). The active ATPase sites in the MCM2-7 ring are formed through the interaction surfaces of two neighboring subunits such that a critical structure of a conserved arginine finger motif is provided in trans relative to the ATP-binding site of the Walker A box of the adjacent subunit. The six ATPase active sites, however, are likely to contribute differentially to the complex helicase activity (PubMed:32453425). Required for the entry in S phase and for cell division (Probable)

The "MCM3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MCM3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MCM3AP | MCM3AP-AS1 | MCM4 | MCM5 | MCM6 | MCM7 | MCM8 | MCM8-MCM9 complex | MCM9 | MCMBP | MCMDC2 | MCOLN1 | MCOLN2 | MCOLN3 | MCPH1 | MCPH1-AS1 | MCPH1-DT | MCRIP1 | MCRIP2 | MCRS1 | MCTP1 | MCTP2 | MCTS1 | MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6 | MED7 | MED8 | MED9 | MEDAG | Mediator Complex | Mediator of RNA Polymerase II Transcription | MEF2A | MEF2B | MEF2C | MEF2C-AS1 | MEF2C-AS2 | MEF2D | MEFV | MEG3 | MEG8